Association Between Visual Acuity and Prospective Fall Risk in Generally Healthy and Active Older Adults: The 3-Year DO-HEALTH Study.

Objective: Although aging has a strong impact on visual acuity (VA) and falls, their interaction is understudied in generally healthy older adults. This study aimed to examine if and to what extent baseline VA is associated with an increased risk of all and injurious falls over 3 years in generally healthy community-dwelling older adults.
Design: Observational analysis of DO-HEALTH, a double-blind, randomized controlled trial.
Setting and Participants: Multicenter trial with 7 European centers: Zurich, Basel, Geneva (Switzerland), Berlin (Germany), Innsbruck (Austria), Toulouse (France), and Coimbra (Portugal), including 2157 community-dwelling adults aged 70 years and older without any major health events in the 5 years prior to enrollment, sufficient mobility, and good cognitive status.
Methods: The numbers of all and injurious falls were recorded prospectively by diary and in-person assessment every 3 months. Decreased VA at baseline was defined as better-eye VA lower than 1.0. We applied negative binomial regression models for all and injurious falls, adjusted for age, sex, prior falls, treatment allocation, study site, baseline body mass index, and use of walking aids.
Results: Among the 2131 participants included in this analysis (mean age: 74.9 years, 61.7% were women, 82.6% at least moderately physically active), 1464 (68.7%) had decreased VA. Overall, 3290 falls including 2116 injurious falls were recorded over 3 years. Decreased VA at baseline was associated with a 22% increased incidence rate of all falls [adjusted incidence rate ratio (aIRR) = 1.22, 95% CI 1.07, 1.38, P = .003] and 20% increased incidence rate of injurious falls (aIRR = 1.20, 95% CI 1.05, 1.37, P = .007).
Conclusions and Implications: Our findings suggest that decreased VA is an independent predictor of an about 20% increased risk of all and injurious falls, highlighting the importance of regular eye examinations and VA measurements for fall prevention, even in generally healthy and active older adults.
Competing Interests: Disclosure As part of the DO-HEALTH independent and investigator-initiated clinical trial, H.A.B.-F. reports, as the principal investigator of the DO-HEALTH trial, grants from the European Commission, the University of Zurich, Nestec, Pfizer Consumer Healthcare, and Streuli Pharma, and nonfinancial support from DSM Nutritional Products and Roche Diagnostics. Further, H.A.B.-F. reports speaker fees from Wild, Pfizer, Vifor, Mylan, Roche Diagnostics, and independent and investigator-initiated grants from Pfizer and from Vifor, outside of the submitted work. E.J.O. was also funded by DO-HEALTH. J.A.K. is a director of Osteoporosis Research Ltd. that maintains FRAX. M.D.B. reports speaking engagements for Roche Pharma (Schweiz) AG and consulting roles for Hoffmann-La Roche Ltd., Roche Pharma (Schweiz) AG, and ZEISS meditec (Deutschland). He is a lead user for Oertli (Schweiz) and holds patents and equity in Ophthorobotics AG. His contracted research includes work with Roche Pharma (Schweiz) AG, Novertis Pharma Schweiz AG, Chengdu Kanghong, and Bayer (Schweiz) AG. He has also received grant support from the W.H. Spross Stiftung zur Förderung der Augenheilkunde and the Stiftung für wissenschaftliche Forschung am Stadtspital Zürich. All other authors declare no competing interests.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)